Horizon Pharma plc (HZNP) has risen sharply, recording gains of 16.06% in the past 4 weeks. However, the stock has corrected -1.36% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.72% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Horizon Pharma plc (NASDAQ:HZNP): The stock opened at $19.19 on Friday but the bulls could not build on the opening and the stock topped out at $19.19 for the day. The stock traded down to $18.74 during the day, due to lack of any buying support eventually closed down at $18.86 with a loss of -1.10% for the day. The stock had closed at $19.07 on the previous day. The total traded volume was 1,902,007 shares.
The stock has recorded a 20-day Moving Average of 6.06% and the 50-Day Moving Average is 10.72%. Horizon Pharma plc is up 15.07% in the last 3-month period. Year-to-Date the stock performance stands at -12.97%.
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical company focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis, inflammation and orphan diseases. The Companys the United States marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, has the United States rights to VIMOVO, has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.